Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
Open Access
- 1 January 2021
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 203 (1), 111-119
- https://doi.org/10.1164/rccm.202001-0135oc
Abstract
Rationale: Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, some patients remain at high risk for an unfavorable treatment outcome. The endTB Observational Study is the largest multicountry cohort of patients with rifampin-resistant TB or MDR-TB treated in routine care with delamanid- and/or bedaquiline-containing regimens according to World Health Organization guidance. Objectives: We report the frequency of sputum culture conversion within 6 months of treatment initiation and the risk factors for nonconversion. Methods: We included patients with a positive baseline culture who initiated a first endTB regimen before April 2018. Two consecutive negative cultures collected 15 days or more apart constituted culture conversion. We used generalized mixed models to derive marginal predictions for the probability of culture conversion in key subgroups. Measurements and Main Results: A total of 1,109 patients initiated a multidrug treatment containing bedaquiline (63%), delamanid (27%), or both (10%). Of these, 939 (85%) experienced culture conversion within 6 months. In adjusted analyses, patients with HIV had a lower probability of conversion (0.73; 95% confidence interval [CI], 0.62–0.84) than patients without HIV (0.84; 95% CI, 0.79–0.90; P = 0.03). Patients with both cavitary disease and highly positive sputum smear had a lower probability of conversion (0.68; 95% CI, 0.57–0.79) relative to patients without either (0.89; 95% CI, 0.84–0.95; P = 0.0004). Hepatitis C infection, diabetes mellitus or glucose intolerance, and baseline resistance were not associated with conversion. Conclusions: Frequent sputum conversion in patients with rifampin-resistant TB or MDR-TB who were treated with bedaquiline and/or delamanid underscores the need for urgent expanded access to these drugs. There is a need to optimize treatment for patients with HIV and extensive disease.Keywords
This publication has 37 references indexed in Scilit:
- Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing lossBMC Infectious Diseases, 2014
- Xpert MTB/RIF as a Measure of Sputum Bacillary Burden. Variation by HIV Status and ImmunosuppressionAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Estimating predicted probabilities from logistic regression: different methods correspond to different target populationsInternational Journal of Epidemiology, 2014
- Hepatitis C Virus Co-Infection Increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity among Patients with Pulmonary TuberculosisPLOS ONE, 2013
- ‘I cry every day’: experiences of patients co‐infected with HIV and multidrug‐resistant tuberculosisTropical Medicine & International Health, 2013
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisEuropean Respiratory Journal, 2012
- Delamanid for Multidrug-Resistant Pulmonary TuberculosisThe New England Journal of Medicine, 2012
- HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect StormThe Journal of Infectious Diseases, 2007
- Antituberculosis Drug–induced HepatotoxicityAmerican Journal of Respiratory and Critical Care Medicine, 1998
- When can odds ratios mislead?BMJ, 1998